Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Rituximab for Untreated Advanced Follicular Lymphoma
NCT02451111Phase 2Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Nov 2015
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of ibrutinib in follicular lymphoma (FL), sponsored by Swiss Group for Clinical Cancer Research. Started Nov 2015; status: terminated.
02
Drugs
ibrutinib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02451111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451111.